This book encompasses an up-to-date, comprehensive review of the state-of-the-art for prostate gland preserving therapies. It provides insight into the latest research and clinical applications of image-guided diagnosis and minimally invasive focal, gland-preserving treatment for prostate cancer. Fully updated and revised, this text evaluates the scientific evidence for the evolving trend to treat intermediate risk, clinically localized prostate cancer in a focally ablative manner with novel gland-preserving, image-targeted therapy methods.
Imaging and Focal Therapy of Early Prostate Cancer, Third Edition opens with a discussion of why patients and clinicians should consider focal therapy, then moves on to consider the question of active surveillance versus focal therapy from a global perspective, with chapters on North American, European, Southeast Asian, and South American perspectives. From there, chapters cover the scientific foundation of focal therapy, current and new approaches to image cancer foci within the prostate (multiparametric ultrasonography, multiparametric magnetic resonance imaging, etc.) and various biopsy techniques. Following this is detailed coverage of patient selection, treatment strategy, adjuvants to enhance therapy, outcomes, and patient centered interests, followed by a discussion of the strengths and limitations of various therapeutic modalities, such as cryotherapy, high intensity focused ultrasound, and photodynamic therapy, follows. The final sections of the book cover the assessment of focal therapy outcomes and look forward to the future of focal therapy for prostate cancer.
Written by experts in the field and lavishly illustrated with detailed line-art and photographs, this text is designed as a comprehensive resource for urologists, radiation oncologists, medical oncologists, radiologists, uropathologists, molecular biologists, biomedical engineers, residents, fellows, nurses and allied professionals, and researchers with an interest in the diagnosis and novel targeted treatment of prostate cancer.